In the early post-stroke phase, Tregs act on peripheral leucocytes to inhibit the production of matrix metalloproteinase-9 (MMP-9) by neutrophils [111,112], thereby protecting the blood–brain barrier, and prevent the activation of effector T cells by secreting anti-inflammatory IL-10 and TGF-β [113]. This evidence concerns the gene MMP9 and stroke disorder.